Effect of docetaxel on the regulation of proliferation and apoptosis of human prostate cancer cells

Yang, Chongyi; Zhang, Weijie; Wang, Jie; Chen, Pengpeng; Jin, Jiang‐Jiang

doi:10.3892/mmr.2019.9998

Cited by 7 publications

(9 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For the docetaxel-treated LNCaP and PC-3 cells, an estimated IC 50 of 1.58 nM and 3.04 nM, respectively, was determined ( Supplementary information; Figure S3 ). This result corresponds with what has been previously reported in the literature [ 50 ]. Similarly, with brusatol-treated LNCaP and PC-3 cells, an IC 50 of 4.15 nM and 15.3 nM, respectively, was obtained ( Figure S3 ).…”

Section: Resultssupporting

confidence: 93%

Preparation, Optimization, and In-Vitro Evaluation of Brusatol- and Docetaxel-Loaded Nanoparticles for the Treatment of Prostate Cancer

Adekiya,

Moore,

Thomas

et al. 2024

Pharmaceutics

View full text Add to dashboard Cite

Challenges to docetaxel use in prostate cancer treatment include several resistance mechanisms as well as toxicity. To overcome these challenges and to improve the therapeutic efficacy in heterogeneous prostate cancer, the use of multiple agents that can destroy different subpopulations of the tumor is required. Brusatol, a multitarget inhibitor, has been shown to exhibit potent anticancer activity and play an important role in drug response and chemoresistance. Thus, the combination of brusatol and docetaxel in a nanoparticle platform for the treatment of prostate cancer is expected to produce synergistic effects. In this study, we reported the development of polymeric nanoparticles for the delivery of brusatol and docetaxel in the treatment of prostate cancer. The one-factor-at-a-time method was used to screen for formulation and process variables that impacted particle size. Subsequently, factors that had modifiable effects on particle size were evaluated using a 24 full factorial statistical experimental design followed by the optimization of drug loading. The optimization of blank nanoparticles gave a formulation with a mean size of 169.1 nm ± 4.8 nm, in agreement with the predicted size of 168.333 nm. Transmission electron microscopy showed smooth spherical nanoparticles. The drug release profile showed that the encapsulated drugs were released over 24 h. Combination index data showed a synergistic interaction between the drugs. Cell cycle analysis and the evaluation of caspase activity showed differences in PC-3 and LNCaP prostate cancer cell responses to the agents. Additionally, immunoblots showed differences in survivin expression in LNCaP cells after treatment with the different agents and formulations for 24 h and 72 h. Therefore, the nanoparticles are potentially suitable for the treatment of advanced prostate cancer.

show abstract

Section: Resultssupporting

confidence: 93%

Preparation, Optimization, and In-Vitro Evaluation of Brusatol- and Docetaxel-Loaded Nanoparticles for the Treatment of Prostate Cancer

Adekiya,

Moore,

Thomas

et al. 2024

Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…In the metastatic setting, several studies have demonstrated an overall survival benefit with the use of docetaxel in both castrate-resistant 4,5,6 and castrate-sensitive disease. 7,8 In the locally advanced setting its utility is theorized to be due to its ability to induce apoptosis of cancer cells by phosphorylation of BCL-2 9 , its well-documented function as a potent radiosensitizer 10 and its ability to target hormone resistant prostate cancer clones 11 .…”

Section: Introductionmentioning

confidence: 99%

“… 7 , 8 In the locally advanced setting its utility is theorized to be due to its ability to induce apoptosis of cancer cells by phosphorylation of BCL-2 9 , its well-documented function as a potent radiosensitizer, 10 and its ability to target hormone-resistant prostate cancer clones. 11 …”

Section: Introductionmentioning

confidence: 99%

Long-Term Outcomes of a Phase I Trial of Weekly Docetaxel, Total Androgen Blockade, and Image Guided Intensity Modulated Radiation Therapy for Localized High-Risk Prostate Adenocarcinoma

McVorran

Keane

Marshall

2022

Advances in Radiation Oncology

View full text Add to dashboard Cite

“…Resisting apoptosis is common in all kinds of tumors. Dysregulation of apoptosis is also regarded as a hallmark of PCa [27][28][29]. Hence, restore the normal apoptotic cell death in PCa is a critical treatment strategy [30][31][32], such as androgen deprivation therapy [33].…”

Section: Discussionmentioning

confidence: 99%

Phosphoribosyl pyrophosphate synthetases 2 knockdown inhibits prostate cancer progression by suppressing cell cycle and inducing cell apoptosis

Qiao¹,

Tan²,

Lv³

et al. 2020

J. Cancer

View full text Add to dashboard Cite

Phosphoribosyl pyrophosphate synthetases 2 (PRPS2) protein function as nucleotide synthesis enzyme that plays vital roles in cancer biology. However, the expression profile and function of PRPS2 in prostate cancer (PCa) remain to be identified. Here we investigated the expression of PRPS2 protein in human PCa and paired normal tissues by immunohistochemistry, meanwhile the regulatory effects on cell proliferation, apoptosis and growth of xenograft tumors in nude mice were evaluated in PCa cells with PRPS2 depletion. Moreover, the signaling pathways were also explored by western blot analysis and quantitative polymerase chain reaction assays. We found that PRPS2 was dramatically upregulated in prostate adenocarcinoma tissues in comparison with normal tissues, and that increased PRPS2 was linked intimately to advanced clinical stage and pT status. Functional experiments showed that knockdown of PRPS2 significantly suppressed cell growth both in vitro and in vivo. In addition, depletion of PRPS2 induced G1 phase cell cycle arrest and elevated cell apoptosis. Silencing of PRPS2 resulted in the decreased expression of Bcl-2 and cyclinD1 and increased levels of Bax, cleavage of caspases-3, caspases-9 and PARP. Furthermore, we also detected PRPS2 expression was significantly induced after DHT treatment, which implied the important role of PRPS2 in oncogenesis of PCa. Taken together, our findings elucidated that PRPS2 may be a potential novel candidate for PCa therapy.

show abstract

Effect of docetaxel on the regulation of proliferation and apoptosis of human prostate cancer cells

Cited by 7 publications

References 32 publications

Preparation, Optimization, and In-Vitro Evaluation of Brusatol- and Docetaxel-Loaded Nanoparticles for the Treatment of Prostate Cancer

Preparation, Optimization, and In-Vitro Evaluation of Brusatol- and Docetaxel-Loaded Nanoparticles for the Treatment of Prostate Cancer

Long-Term Outcomes of a Phase I Trial of Weekly Docetaxel, Total Androgen Blockade, and Image Guided Intensity Modulated Radiation Therapy for Localized High-Risk Prostate Adenocarcinoma

Phosphoribosyl pyrophosphate synthetases 2 knockdown inhibits prostate cancer progression by suppressing cell cycle and inducing cell apoptosis

Contact Info

Product

Resources

About